Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 162

Results For "RSE"

2077 News Found

Mylab launches RT-PCR test for Ankylosing Spondylitis ahead of the World AS Day
Medical Device | May 04, 2022

Mylab launches RT-PCR test for Ankylosing Spondylitis ahead of the World AS Day

This RT-PCR diagnostic kit helps in diagnosis of AS by detecting HLAB27 gene


StanPlus appoints Gurjit Singh as COO and Founding Member
People | May 02, 2022

StanPlus appoints Gurjit Singh as COO and Founding Member

He will be leading the business, operations, P&L, and growth strategy for StanPlus


Physicians foresee an Alzheimer's Disease treatment revolution supported by advanced testing tools
Biotech | May 02, 2022

Physicians foresee an Alzheimer's Disease treatment revolution supported by advanced testing tools

Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education


ASPIRE 2022 Congress: Recognising the 'tip of the iceberg' in the complex and chronic effects of endometriosis
Public Health | May 01, 2022

ASPIRE 2022 Congress: Recognising the 'tip of the iceberg' in the complex and chronic effects of endometriosis

It affects up to 10 per cent of women of reproductive age around the world


GeneStore launches Centre of Excellence in Gurugram, India
News | May 01, 2022

GeneStore launches Centre of Excellence in Gurugram, India

Center of Excellence for Molecular Diagnostics and Proteomics will enable affordable diagnostics for infectious diseases in India


Ultomiris approved in the US for adults with generalised myasthenia gravis
Drug Approval | April 29, 2022

Ultomiris approved in the US for adults with generalised myasthenia gravis

Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks


Camzyos is the first and only USFDA-approved cardiac myosin inhibitor
Biotech | April 29, 2022

Camzyos is the first and only USFDA-approved cardiac myosin inhibitor

Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo


Diadem announces publication of peer-reviewed article on Alzheimer’s disease
Biotech | April 28, 2022

Diadem announces publication of peer-reviewed article on Alzheimer’s disease

It includes multiple studies demonstrating that post-translational modifications of conformational variants of p53 are associated with the pathogenesis of Alzheimer's Disease


Sanofi continues to deliver strong business
News | April 28, 2022

Sanofi continues to deliver strong business

Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate


USFDA grants Breakthrough Device designation to Nocria’s Migraine treatment
Biotech | April 28, 2022

USFDA grants Breakthrough Device designation to Nocria’s Migraine treatment

Nocria’s hand-held device uses gentle, controlled puffs of air in the ears for treating migraine attacks